Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) EBITDA (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed EBITDA for 6 consecutive years, with -$54.6 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA rose 31.26% to -$54.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$274.8 million, a 18.83% increase, with the full-year FY2025 number at -$274.8 million, up 18.83% from a year prior.
  • EBITDA was -$54.6 million for Q4 2025 at Relay Therapeutics, up from -$73.5 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$42.2 million in Q1 2021 to a low of -$193.5 million in Q2 2021.
  • A 5-year average of -$80.5 million and a median of -$77.8 million in 2022 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: plummeted 603.88% in 2021, then soared 58.92% in 2022.
  • Relay Therapeutics' EBITDA stood at -$68.6 million in 2021, then rose by 5.86% to -$64.5 million in 2022, then dropped by 24.44% to -$80.3 million in 2023, then grew by 1.0% to -$79.5 million in 2024, then soared by 31.26% to -$54.6 million in 2025.
  • Per Business Quant, the three most recent readings for RLAY's EBITDA are -$54.6 million (Q4 2025), -$73.5 million (Q3 2025), and -$70.6 million (Q2 2025).